IL321139A - Polypeptide inhibitor, method for its preparation and use - Google Patents

Polypeptide inhibitor, method for its preparation and use

Info

Publication number
IL321139A
IL321139A IL321139A IL32113925A IL321139A IL 321139 A IL321139 A IL 321139A IL 321139 A IL321139 A IL 321139A IL 32113925 A IL32113925 A IL 32113925A IL 321139 A IL321139 A IL 321139A
Authority
IL
Israel
Prior art keywords
amino acid
alkyl
integers
compound
added
Prior art date
Application number
IL321139A
Other languages
English (en)
Hebrew (he)
Inventor
Jiaqiang Dong
Wensheng Yu
Yun Chen
Bao Cheng
Zhen Gong
Original Assignee
Shanghai Hansoh Biomedical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiaqiang Dong
Wensheng Yu
Yun Chen
Bao Cheng
Zhen Gong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Jiaqiang Dong, Wensheng Yu, Yun Chen, Bao Cheng, Zhen Gong filed Critical Shanghai Hansoh Biomedical Co Ltd
Publication of IL321139A publication Critical patent/IL321139A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL321139A 2022-11-30 2023-11-30 Polypeptide inhibitor, method for its preparation and use IL321139A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202211530438 2022-11-30
CN202310206299 2023-03-03
CN202310261818 2023-03-15
CN202310349519 2023-03-31
CN202311144489 2023-09-05
PCT/CN2023/135637 WO2024114762A1 (zh) 2022-11-30 2023-11-30 一种多肽抑制剂、其制备方法和应用

Publications (1)

Publication Number Publication Date
IL321139A true IL321139A (en) 2025-07-01

Family

ID=91323029

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321139A IL321139A (en) 2022-11-30 2023-11-30 Polypeptide inhibitor, method for its preparation and use

Country Status (10)

Country Link
US (1) US20260193294A1 (cg-RX-API-DMAC7.html)
EP (1) EP4628499A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025540765A (cg-RX-API-DMAC7.html)
KR (1) KR20250111134A (cg-RX-API-DMAC7.html)
CN (1) CN120202212A (cg-RX-API-DMAC7.html)
AU (1) AU2023404553A1 (cg-RX-API-DMAC7.html)
IL (1) IL321139A (cg-RX-API-DMAC7.html)
MX (1) MX2025006152A (cg-RX-API-DMAC7.html)
TW (1) TW202440611A (cg-RX-API-DMAC7.html)
WO (1) WO2024114762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242221A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 新型修饰侧链、其制备方法和应用
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026052109A1 (zh) * 2024-09-06 2026-03-12 上海翰森生物医药科技有限公司 一种多肽抑制剂的药物组合物及其用途
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201810154WA (en) * 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP4021919A1 (en) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
MX2022008740A (es) * 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) * 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) * 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor

Also Published As

Publication number Publication date
JP2025540765A (ja) 2025-12-16
MX2025006152A (es) 2025-07-01
CN120202212A (zh) 2025-06-24
US20260193294A1 (en) 2026-07-09
AU2023404553A1 (en) 2025-07-10
TW202440611A (zh) 2024-10-16
WO2024114762A1 (zh) 2024-06-06
KR20250111134A (ko) 2025-07-22
EP4628499A1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
KR20250111134A (ko) 폴리펩티드 억제제, 이의 제조 방법 및 응용
CZ285104B6 (cs) Deriváty kyseliny žlučové, způsob jejich přípravy a použití těchto sloučenin jako léčiv
SA02230260B1 (ar) مشتقات تترا هيدروكينولين
Kuefner et al. Carboxypeptidase-mediated release of methotrexate from methotrexate. alpha.-peptides
EP3820842B1 (en) (r)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as ep4 receptor antagonist
CA2228060C (en) Isoxazole and crotonamide derivatives and their use as pharmaceuticals and diagnostics
JPS61189298A (ja) 新規オリゴペプチジルアルギニノール誘導体
EP0505680A1 (en) Octapeptide or heptapeptide derivatives, a process for preparing them as well as medicaments containing these compounds and the use of them
CA2590750A1 (en) Myd88 homodimerization inhibitors
US12383535B2 (en) Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor
FI60565B (fi) Cefalexin-bis-(n,n-dimetylformamid)-solvat anvaendbart som mellanprodukt vid framstaellningen av cefalexin och foerfarande foer framstaellning av detta
TW202435884A (zh) 用於抑制tnf受體1活性之環狀肽
KR20190120288A (ko) 화학 발광 안드로스텐디온 컨쥬게이트
RU2328496C2 (ru) Пиразолхинолины с иммуномодулирующей активностью
JPH02229804A (ja) ペプチド合成用担体
US4038282A (en) Pyridyl-4-methyl-succinimidocarbonate and process for its preparation
JPH02270895A (ja) T―リンパ球の成熟及びマクロファージの活性を阻害する新規ペプチド、それらを含む医薬組成物及びそれらの調製方法
SU1316556A3 (ru) Способ получени производных пролина или их фармацевтически приемлемых солей
SCHULTZ et al. Synthesis and conformational properties of a synthetic cyclic peptide for the active site of α‐chymotrypsin
JPS5892642A (ja) 新規なペプチドおよびそれらの製造法
CN109400597B (zh) 一种基于vegfr-2抑制剂abt-869的蛋白降解靶向嵌合体及制备方法和应用
EP1242363B1 (en) Cd45 inhibitors
US3780015A (en) Process for preparing lysine containing peptides
CN121005656B (zh) 一种具有吡啶酮结构的化合物及其在医药上的应用
SU702030A1 (ru) -Пептидилтиогликозиды ацетил- -глюкозамина в качестве лигандов в аффинной хроматографии